Black Rock Inc. Amylyx Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,669,741 shares of AMLX stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,669,741

Previous 4,474,722 40.34%

Holding current value

$10.3 Million

Previous $12.7 Million 60.09%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.71 $2.92 Million - $4.89 Million	-1,804,981 Reduced 40.34%	2,669,741 $5.07 Million
Q1 2024 May 10, 2024	BUY	$2.71 - $19.57 $1.28 Million - $9.24 Million	472,388 Added 11.8%	4,474,722 $12.7 Million
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $5.15 Million - $7.88 Million	426,875 Added 11.94%	4,002,334 $58.9 Million
Q3 2023 Nov 13, 2023	BUY	$18.08 - $23.45 $1.27 Million - $1.65 Million	70,174 Added 2.0%	3,575,459 $65.5 Million
Q2 2023 Aug 11, 2023	SELL	$20.98 - $31.42 $2.3 Million - $3.44 Million	-109,633 Reduced 3.03%	3,505,285 $75.6 Million
Q1 2023 May 12, 2023	SELL	$27.71 - $40.93 $55,641 - $82,187	-2,008 Reduced 0.06%	3,614,918 $106 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $39.3 Million - $51.9 Million	1,321,092 Added 57.54%	3,616,926 $134 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $27.2 Million - $49.1 Million	1,586,402 Added 223.62%	2,295,834 $64.6 Million
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $939,073 - $2.73 Million	137,091 Added 23.95%	709,432 $13.7 Million
Q1 2022 May 12, 2022	BUY	$12.85 - $32.9 $7.35 Million - $18.8 Million	572,341 New	572,341 $7.35 Million

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $227M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account